Javascript must be enabled to continue!
Frequency of Nephrotoxicity with Vancomycin and Aminoglycoside Antibiotic Therapy
View through CrossRef
Three hundred and thirty four patients receiving aminoglycosides and/or vancomycin therapy for at least 72 hours were retrospectively reviewed for the development of nephrotoxicity. The patients' vancomycin and aminoglycoside serum concentrations were monitored by our clinical pharmacokinetics service. The average age, weight, and serum creatinine of the patients were 67.8 years, 71.3 kg, and 1.03 mg/dL, respectively. Nephrotoxicity occurred in 30 patients, but only 8 of these cases of renal toxicity (2.4%) were attributed to the use of vancomycin and/or aminoglycosides. The remaining 22 patients had other factors known to contribute to renal failure. Nephrotoxicity with aminoglycosides was more frequent than with vancomycin (2.8% versus 1.1%, respectively). Alarmingly, the frequency of renal toxicity increased by about four-fold when vancomycin was administered concomitantly with an aminoglycoside. Although further analysis is needed, preexisting renal impairment seems to be the major contributing factor for nephrotoxicity in our study.
Title: Frequency of Nephrotoxicity with Vancomycin and Aminoglycoside Antibiotic Therapy
Description:
Three hundred and thirty four patients receiving aminoglycosides and/or vancomycin therapy for at least 72 hours were retrospectively reviewed for the development of nephrotoxicity.
The patients' vancomycin and aminoglycoside serum concentrations were monitored by our clinical pharmacokinetics service.
The average age, weight, and serum creatinine of the patients were 67.
8 years, 71.
3 kg, and 1.
03 mg/dL, respectively.
Nephrotoxicity occurred in 30 patients, but only 8 of these cases of renal toxicity (2.
4%) were attributed to the use of vancomycin and/or aminoglycosides.
The remaining 22 patients had other factors known to contribute to renal failure.
Nephrotoxicity with aminoglycosides was more frequent than with vancomycin (2.
8% versus 1.
1%, respectively).
Alarmingly, the frequency of renal toxicity increased by about four-fold when vancomycin was administered concomitantly with an aminoglycoside.
Although further analysis is needed, preexisting renal impairment seems to be the major contributing factor for nephrotoxicity in our study.
Related Results
598. Area under the curve-guided vancomycin monitoring and risk of nephrotoxicity in non-Staphylococcus aureus infections: A case-control study
598. Area under the curve-guided vancomycin monitoring and risk of nephrotoxicity in non-Staphylococcus aureus infections: A case-control study
Abstract
Background
Area under the curve (AUC)-guided monitoring of vancomycin for the treatment of Staphylococcus aureus (SA) i...
Association between Awareness on Antibiotic Resistance and Antibiotic Misuse Among Saudi University Students
Association between Awareness on Antibiotic Resistance and Antibiotic Misuse Among Saudi University Students
Background:
Saudi Arabia has the highest prevalence of resistant pathogens in the Gulf Region, with a rapid increase in antibiotic resistance seen in recent years. ...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Predicting the intestinal permeability and oral absorbable fraction of Vancomycin–loaded Eudragit RS-100 nanoparticles using single-pass intestinal perfusion in rats
Predicting the intestinal permeability and oral absorbable fraction of Vancomycin–loaded Eudragit RS-100 nanoparticles using single-pass intestinal perfusion in rats
Abstract
One of the important factors which influence the efficacy of antibiotics is the size of the particle that affects the permeability and penetration of antimicrobial...
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide
LY333328 is a semisynthetic N-alkyl derivative of LY264826, a naturally occurring structural analog of vancomycin. LY333328 was evaluated for its in vitro inhibitory and bactericid...
Rosemary: A Promising Therapeutic Agent in Alleviating Nephrotoxicity
Rosemary: A Promising Therapeutic Agent in Alleviating Nephrotoxicity
Background: Nephrotoxicity, kidney damage caused by a variety of chemicals, presents a significant challenge in the medical field. To address nephrotoxicity, innovative therapeutic...
Hand-mixed vancomycin versus commercial tobramycin cement revisited: A study on mechanical and antibacterial properties
Hand-mixed vancomycin versus commercial tobramycin cement revisited: A study on mechanical and antibacterial properties
Purpose: Arthroplasty-related infection has grown worldwide. Revision procedures for infection are associated with longer operating time, superior amounts of blood loss, and substa...
Identification of Vancomycin Resistant Enterococcus Genes in Clinical Isolates
Identification of Vancomycin Resistant Enterococcus Genes in Clinical Isolates
Vancomycin resistant enterococci (VRE) nosocomial diseases are rapidly spreading across the world. To treat these diseases is becoming a great challenge due to antibiotic resistanc...

